These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37090101)

  • 41. Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review.
    Juarez-Garcia A; Sharma R; Hunger M; Kayaniyil S; Penrod JR; Chouaïd C
    Lung Cancer; 2022 Apr; 166():205-220. PubMed ID: 35316754
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunotherapy with toripalimab for lung adenocarcinoma in a real-world patient with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 4: a case report.
    Xue Y; Zheng K; Xue J
    Ann Palliat Med; 2021 Sep; 10(9):10114-10123. PubMed ID: 34628932
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era.
    Friedlaender A; Banna GL; Buffoni L; Addeo A
    Curr Oncol Rep; 2019 Nov; 21(12):107. PubMed ID: 31768759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice.
    Steffen McLouth LE; Lycan TW; Levine BJ; Gabbard J; Ruiz J; Farris M; Grant SC; Pajewski NM; Weaver KE; Petty WJ
    Clin Lung Cancer; 2020 May; 21(3):255-263.e4. PubMed ID: 31917067
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
    Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
    Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.
    Felip E; Ardizzoni A; Ciuleanu T; Cobo M; Laktionov K; Szilasi M; Califano R; Carcereny E; Griffiths R; Paz-Ares L; Duchnowska R; Garcia MA; Isla D; Jassem J; Appel W; Milanowski J; Van Meerbeeck JP; Wolf J; Li A; Acevedo A; Popat S
    Eur J Cancer; 2020 Mar; 127():160-172. PubMed ID: 32028209
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Administration of Immune Checkpoint Inhibitors Near the End of Life.
    Bloom MD; Saker H; Glisch C; Ramnaraign B; George TJ; Markham MJ; Kelkar AH
    JCO Oncol Pract; 2022 Jun; 18(6):e849-e856. PubMed ID: 35254868
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario.
    Singh A; Kapoor A; Noronha V; Patil V; Menon N; Mahajan A; Janu A; Purandare N; Kaushal R; Prabhash K
    Ecancermedicalscience; 2022; 16():1407. PubMed ID: 36072236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
    Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
    Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study.
    Mollica V; Rizzo A; Marchetti A; Tateo V; Tassinari E; Rosellini M; Massafra R; Santoni M; Massari F
    Clin Exp Med; 2023 Dec; 23(8):5039-5049. PubMed ID: 37535194
    [TBL] [Abstract][Full Text] [Related]  

  • 52. First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
    Li JR; Wang SS; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Yang CK
    Anticancer Res; 2023 Mar; 43(3):1331-1339. PubMed ID: 36854504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 - Systematic review and meta-analysis.
    Tomasik B; Bieńkowski M; Braun M; Popat S; Dziadziuszko R
    Lung Cancer; 2021 Aug; 158():97-106. PubMed ID: 34144405
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer, bladder cancer, and melanoma: An electronic health record study.
    Sadetsky N; Chuo CY; Davidoff AJ
    Pharmacoepidemiol Drug Saf; 2021 Sep; 30(9):1233-1241. PubMed ID: 34145696
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer.
    Li C; Shi M; Lin X; Zhang Y; Yu S; Zhou C; Yang N; Zhang J; Zhang F; Lv T; Liu H; Song Y
    Transl Lung Cancer Res; 2021 Feb; 10(2):776-789. PubMed ID: 33718021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings.
    Yoneda T; Sone T; Koba H; Shibata K; Suzuki J; Tani M; Nishitsuji M; Nishi K; Kobayashi T; Shirasaki H; Araya T; Kita T; Kase K; Yamamura K; Terada N; Nishikawa S; Tambo Y; Kimura H; Kasahara K
    Clin Lung Cancer; 2022 Sep; 23(6):467-476. PubMed ID: 35618628
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings.
    Kapoor A; Noronha V; Patil VM; Menon N; Joshi A; Abraham G; Prabhash K
    Medicine (Baltimore); 2021 Apr; 100(13):e25115. PubMed ID: 33787593
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
    Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
    Front Immunol; 2022; 13():968729. PubMed ID: 35967438
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
    BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy?
    Baldotto CS; Cronemberger EH; de Biasi P; Zamboni M; Sousa A; Zukin M; Small IA; Ferreira CG
    Support Care Cancer; 2012 Nov; 20(11):2721-7. PubMed ID: 22322592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.